Pfizer, Inc. (PFE) analyst actions
Rating and price-target actions on PFE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PFE overview →
2 measured PFE analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen | Press release | -0.06% | +0.30% | |
| ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV | Press release | -0.04% | +0.33% |
Keep exploring
More PFE: earnings → · SEC filings → · PFE overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| RETROPHIN INC (RTRX) | 723 | +0.06% | 52% |
| IsoRay, Inc. (DE) (ISR) | 722 | -0.01% | 45% |
| ESSA Pharma Inc. (EPIX) | 718 | 0.00% | 38% |
| Tricida, Inc. (TCDA) | 715 | +0.06% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.